A human monoclonal antibody blocking SARS-CoV-2 infection
Publication date
2020
Authors
Wang, Chunyan
Li, Wentao
Drabek, Dubravka
Okba, Nisreen M A
van Haperen, Rien
Osterhaus, Albert D M E
van Kuppeveld, Frank J M
Haagmans, Bart L
Grosveld, Frank
Bosch, Berend Jan
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
Keywords
SDG 3 - Good Health and Well-being
Citation
Wang, C, Li, W, Drabek, D, Okba, N M A, van Haperen, R, Osterhaus, A D M E, van Kuppeveld, F J M, Haagmans, B L, Grosveld, F & Bosch, B-J 2020, 'A human monoclonal antibody blocking SARS-CoV-2 infection', Nature Communications, vol. 11, no. 1, 2251, pp. 1-6. https://doi.org/10.1038/s41467-020-16256-y